Contents 3 min read

Claim and source comparison

Comparison scope: Singh 2023, Fernandez 2025, Sun 2016 and Ghandforoush-Sattari 2010 abstracts; official EFSA 2009 safety summary. Species, population and exposure limits are retained; not independent clinical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

Singh 2023 reported improved lifespan in mice and worms and health measures in monkeys with taurine; lifespan extension was not demonstrated in monkeys or humans. Human associations were not a supplementation trial.

Animal mechanisms do not establish human anti-aging treatment, sleep/anxiety benefit or personal dosing. Healthspan and total lifespan are different outcomes.

Source 1 · Abstract read

Human observational study

Fernandez 2025: Circulating taurine increased or remained unchanged with age in three human cohorts and observations in monkeys and mice. Health associations varied; declining taurine was not a universal aging marker.

The human component is observational, with longitudinal and cross-sectional measures. It does not test supplementation efficacy or inefficacy; a single plasma value diagnoses neither aging nor supplement need.

Source 5 · Abstract read

Human pharmacokinetic study

Ghandforoush-Sattari 2010: In eight healthy fasted men given 4 g oral taurine, plasma elimination half-life was 1.0 ±0.3 hours and Tmax 1.5 ±0.6 hours. This is a small human pharmacokinetic study.

About one hour is the educational model's source value; 4 g is not personal-use advice. Tmax is not clinical onset; endogenous taurine, brain levels and whole-body stores are not measured by this curve.

Source 7 · Abstract read

Human randomized controlled trial

Sun 2016: 120 people with prehypertension were randomized to 1.6 g/day taurine or placebo for 12 weeks. Mean clinic systolic reduction from baseline was 7.2/2.6 mmHg for taurine/placebo; this is not an extra 7.2 mmHg over placebo.

A patient-group blood-pressure result is neither cognitive benefit nor a direct interaction trial with antihypertensive drugs. Possible additive hypotension requires clinical assessment; do not independently change treatment.

Source 8 · Abstract read

Regulatory scientific assessment

EFSA's 2009 opinion assessed taurine and glucuronolactone as individual ingredients at modeled energy-drink exposure. It did not assess whole energy drinks, every mixture or cognitive efficacy.

A historical exposure assessment is not approval of 6 g/day supplementation for everyone or a personal safe upper limit. Caffeine, alcohol, pregnancy and long-term high-dose safety cannot be inferred from it.

Source 6 · Official summary read

Our evidence and source methodology

taurine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Taurine?

Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking.

Taurine is an amino sulfonic acid with a sulfonic acid group instead of a carboxylic acid group. It is not a standard protein-building amino acid.

Longevity Connection

Singh 2023 reported improved lifespan in mice and worms and health measures in monkeys with taurine; lifespan extension was not demonstrated in monkeys or humans. Human associations were not a supplementation trial.

Animal mechanisms do not establish human anti-aging treatment, sleep/anxiety benefit or personal dosing. Healthspan and total lifespan are different outcomes.

Fernandez 2025: Circulating taurine increased or remained unchanged with age in three human cohorts and observations in monkeys and mice. Health associations varied; declining taurine was not a universal aging marker.

The human component is observational, with longitudinal and cross-sectional measures. It does not test supplementation efficacy or inefficacy; a single plasma value diagnoses neither aging nor supplement need.

Clinical Trials

Sun 2016: 120 people with prehypertension were randomized to 1.6 g/day taurine or placebo for 12 weeks. Mean clinic systolic reduction from baseline was 7.2/2.6 mmHg for taurine/placebo; this is not an extra 7.2 mmHg over placebo.

A patient-group blood-pressure result is neither cognitive benefit nor a direct interaction trial with antihypertensive drugs. Possible additive hypotension requires clinical assessment; do not independently change treatment.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Ghandforoush-Sattari 2010: In eight healthy fasted men given 4 g oral taurine, plasma elimination half-life was 1.0 ±0.3 hours and Tmax 1.5 ±0.6 hours. This is a small human pharmacokinetic study.

About one hour is the educational model's source value; 4 g is not personal-use advice. Tmax is not clinical onset; endogenous taurine, brain levels and whole-body stores are not measured by this curve.

Safety and Side Effects

EFSA's 2009 opinion assessed taurine and glucuronolactone as individual ingredients at modeled energy-drink exposure. It did not assess whole energy drinks, every mixture or cognitive efficacy.

A historical exposure assessment is not approval of 6 g/day supplementation for everyone or a personal safe upper limit. Caffeine, alcohol, pregnancy and long-term high-dose safety cannot be inferred from it.

A human taurine trial found lower blood pressure; possible additional lowering with antihypertensives needs assessment. This does not mean the combination was directly tested. EFSA's energy-drink ingredient assessment is not general supplement safety; missing records do not establish safety.

Sources

  1. Singh P, et al. (2023). Taurine deficiency as a driver of aging. Science, 380(6649), eabn9257. PubMed · PMID 37289866
  2. Jakaria M, et al. (2019). Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms. Redox Biology, 24, 101223. PubMed · PMID 31141786
  3. Bkaily G, et al. (2020). Taurine and cardiac disease: State of the art and perspectives. Canadian Journal of Physiology and Pharmacology. PubMed · PMID 31560859
  4. El Idrissi A, Trenkner E. (2004). Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochemical Research, 29(1), 189–197. PubMed · PMID 14992278
  5. Fernandez ME, et al. (2025). Is taurine an aging biomarker?. Science, 388(6751), eadl2116. https://doi.org/10.1126/science.adl2116 PubMed · PMID 40472098
  6. European Food Safety Authority (EFSA). (2009). The use of taurine and D-glucurono-gamma-lactone as constituents of the so-called “energy” drinks. EFSA Journal, 7(2), 935. https://doi.org/10.2903/j.efsa.2009.935 Publisher record · DOI · European Food Safety Authority
  7. Ghandforoush-Sattari M, et al. (2010). Pharmacokinetics of oral taurine in healthy volunteers. Journal of amino acids, 2010, 346237. https://doi.org/10.4061/2010/346237 PubMed · PMID 22331997
  8. Sun Q, et al. (2016). Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. Hypertension, 67(3), 541-9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06624 PubMed · PMID 26781281

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions